

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/DK05/000201

International filing date: 22 March 2005 (22.03.2005)

Document type: Certified copy of priority document


Document details: Country/Office: US
Number: 60/557,985
Filing date: 31 March 2004 (31.03.2004)

Date of receipt at the International Bureau: 07 April 2005 (07.04.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse



THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

June 30, 2004

**THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A
FILING DATE UNDER 35 USC 111.**

APPLICATION NUMBER: 60/557,985

FILING DATE: March 31, 2004

DK / 05 / 201

**By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS**



**P. R. GRANT
Certifying Officer**

033104

17707 U.S. PTO

Attorney Docket No.: COMB-24005-PR1

PATENT

22154 U.S. PTO
60/557985

033104

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
FILING UNDER 37 C.F.R.1.53(C)**

Mail Stop Provisional Patent
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Express Mail Label No. EL985883462US
Date of Deposit: March 31, 2004

Sir:

This is a request for filing a provisional application under 37 C.F.R. 1.53(c), of the following inventors:

**Patrizia CALI, a citizen of Italy, residing at J.C. Christensengade 2A,
DK-2300, Copenhagen, Denmark;**

**Anders HJELMENCRA NTZ, a citizen of Sweden, residing at
Sidsbäckgränd 7, SE-21620 Malmö, Sweden;**

**Lars NAERUM, a citizen of Denmark, residing at Alrunevej 14
DK-2900 Hellerup Denmark**

for the application entitled "PEPTIDE DEFORMYLASE INHIBITORS".

The provisional application contains:

52 pages of specification
0 sheet of drawings

Address all future communications to:

Cheryl H. Agris, Ph.D.
Attorney at Law
P.O. Box 806
Pelham, N.Y. 10803
(914) 712-0093
Customer No. 25538

☒ Applicant claims small entity status.

☐ A check or money order is enclosed to cover the filing fee of insert amount.

[x] Payment by credit card of the filing fee of \$80. Form PTO-2038 is attached

Respectfully submitted,

Date: 3/31/04

Cheryl H. Agnis

Cheryl H. Agnis, Ph.D., Reg. No. 34,086

Attorney at Law

P.O. Box 806

Pelham, N.Y. 10803

(914) 712-0093

Attorney Docket No.: COMB-24005-PR1

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
EXPRESS MAIL CERTIFICATE**

Mail Stop Provisional Patent
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Re: U.S. Provisional Application for
"PEPTIDE DEFORMYLASE INHIBITORS"
Applicants: Cali et al.

Sir:


Express Mail Label No. EL985883428US
Date of Deposit: March 31, 2004

I hereby certify that the following attached paper(s) or fee

1. Filing Under 37 C.F.R. 1.53(c)
2. Provisional Application (52 pages of specification)
3. PTO-2038 (\$80.00)

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee under 37 C.F.R. 1.10 on the date indicated above and is addressed to Mail Stop Provisional Patent, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Cheryl H. Agris
(Name of person mailing paper(s) or fee)


(Signature of person mailing paper(s) or fee)

Mailing address:

P.O. Box 806
Pelham, N.Y. 10803
(914) 712-0093

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PATENT APPLICATION SERIAL NO. _____

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
FEE RECORD SHEET

04/13/2004 STEUMEL1 00000085 60557985

01 FC:2005

80.00 0P

PTO-1556
(5/87)

*U.S. Government Printing Office: 2002 — 489-257/80033

72703-dk01

1

PEPTIDE DEFORMYLASE INHIBITORS

The present invention relates to novel enzyme inhibitors, more specifically to inhibitors of polypeptide deformylase useful in the treatment/prevention of infections and other diseases in which polypeptide deformylases are involved, especially in the treatment of bacterial and parasitic infections. More specifically the invention relates to benzothiazines capable of inhibiting bacterial peptide deformylase, also known as PDF, an enzyme that catalyzes the deformylation of formyl-L-methionyl peptides.

10 BACKGROUND OF THE INVENTION


Peptide deformylase (EC 3.4.1.88), also known as PDF, is an enzyme that catalyzes the deformylation of formyl-L-methionyl peptides. PDF removes the formyl group from the N-terminal Met of newly synthesized proteins, i.e. catalyzes the conversion of formyl-L-methionyl peptide to methionyl peptide (Adams and Capecchi, 1966; Adams, 1968).

PDF is essential to bacteria, and bacterial peptide deformylase (PDF) is now widely recognised as an attractive target for antibacterial chemotherapy (Giglione *et al.*, 2000; Giglione and McInnell, 2001; Pei, 2001; Yuan *et al.*, 2001; Clements *et al.*, 2002). Deformylation is a crucial step in bacterial protein biosynthesis and PDF is an essential ingredient in bacterial growth, with the gene encoding PDF present in all sequenced pathogenic bacterial genomes.

Novel antibacterial compounds are urgently needed due to the growing resistance exhibited by both Gram-negative and Gram-positive bacteria and other microorganisms. Traditional antibiotics have targeted pathways unique to bacterial replication and maintenance. However, new pathways are not being targeted in a manner that outpaces the growth of bacterial resistance. Thus, novel compounds and strategies are greatly needed that can be used to eradicate resistant bacteria.

SUMMARY OF THE INVENTION

The present invention relates to compounds of the general formula (I)



72703-dk01

2

or a pharmaceutically acceptable salt or ester thereof,

wherein R_1 , R_2 , R_3 , n , m and X are as defined in the detailed part of this description.

It is contemplated that the compounds of the invention are useful for the treatment of
5 infections caused by bacteria or parasites. It is especially contemplated that the compounds of
the present invention are useful for the treatment of infections fully or partly caused by
Gram-positive or Gram-negative bacteria such as *Escherichia coli* and *Staphylococcus aureus*
or by a parasite such as *Plasmodium falciparum*.

It is an object of the invention to provide novel compounds having pharmacological
10 activity as inhibitors of PDF.

Further objects will become apparent from the following description.

DETAILED DESCRIPTION OF THE INVENTION

15 Definitions

The terminology used herein is for the purpose of describing particular embodiments
only, and is not intended to be limiting, since the scope of the present invention will be
limited only by the appended claims.

Where a range of values is provided, it is understood that each intervening value, to
20 the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between
the upper and lower limit of that range and any other stated or intervening value in that stated
range is encompassed within the invention. The upper and lower limits of these smaller
ranges may independently be included in the smaller ranges is also encompassed within the
invention, subject to any specifically excluded limit in the stated range. Where the stated
25 range includes one or both of the limits, ranges excluding either both of those included limits
are also included in the invention.

Unless defined otherwise, all technical and scientific terms used herein have the same
meaning as commonly understood by one of ordinary skill in the art to which this invention
belongs. Although any methods and materials similar or equivalent to those described herein
30 can also be used in the practice or testing of the present invention, the preferred methods and
materials are now described.

It must be noted that as used herein and in the appended claims, the singular forms
"a," "and" and "the" include plural references unless the context clearly dictates otherwise.

72703-dk01

3

The term "peptide deformylase" or "PDF" as used herein is intended to mean peptide deformylase (EC 3.4.1.88) also known as PDF, which catalyzes the conversion of the N-terminal formyl-L-methionyl peptide to methionyl peptide in newly synthesized proteins.

5 The term "treatment" is defined as the management and care of a patient for the purpose of combating the disease, condition, or disorder and includes the administration of a compound of the present invention to prevent the onset of the symptoms or the complications, or alleviating the symptoms or the complications, or eliminating the disease, condition, or disorder.

10 As used herein, alone or in combination, the term "C₁₋₆ alkyl" denotes a straight or branched, saturated hydrocarbon chain having from one to six carbon atoms. C₁₋₆ alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, n-pentyl, iso-pentyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, iso-hexyl, 4-methylpentyl, neopentyl, 2,2-dimethylpropyl and the like.

15 As used herein, alone or in combination, the term "C₂₋₆ alkenyl" denotes a straight or branched, unsaturated hydrocarbon chain having from two to six carbon atoms and at least one double bond. C₂₋₆ alkenyl groups include, but are not limited to, vinyl, 1-propenyl, allyl, iso-propenyl, n-butenyl, n-pentenyl, n-hexenyl and the like.

20 The term "C₁₋₆ alkoxy" as used herein, alone or in combination, is intended to include those C₁₋₆ alkyl groups of the designated length in either a linear or branched or cyclic configuration linked through an ether oxygen having its free valence bond from the ether oxygen. Examples of linear alkoxy groups are methoxy, ethoxy, propoxy, butoxy, pentoxy and hexoxy. Examples of branched alkoxy are iso-propoxy, sec-butoxy, tert-butoxy, iso-pentoxy and iso-hexoxy. Examples of cyclic alkoxy are cyclopropyloxy, cyclobutyloxy, cyclopentyloxy and cyclohexyloxy.

25 The term "C₃₋₁₀ cycloalkyl" as used herein denotes a radical of one or more saturated mono-, bi-, tri- or spirocyclic hydrocarbon having from three to ten carbon atoms. Examples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, bicyclo[3.2.1]octyl, spiro[4.5]decyl, norpinyl, norbornyl, norcaryl, adamantyl and the like.

30 The term "C₃₋₇ heterocycloalkyl" as used herein denotes a radical of a totally saturated heterocycle like a cyclic hydrocarbon containing one or more heteroatoms selected from nitrogen, oxygen and sulphur independently in the cycle. Examples of heterocycles include, but are not limited to, pyrrolidine (1-pyrrolidine, 2-pyrrolidine, 3-pyrrolidine, 4-pyrrolidine, 5-pyrrolidine), pyrazolidine (1-pyrazolidine, 2-pyrazolidine, 3-pyrazolidine, 4-pyrazolidine,

72703-dk01

4

5-pyrazolidine), imidazolidine (1-imidazolidine, 2-imidazolidine, 3-imidazolidine, 4-imidazolidine, 5-imidazolidine), thiazolidine (2-thiazolidine, 3-thiazolidine, 4-thiazolidine, 5-thiazolidine), piperidine (1-piperidine, 2-piperidine, 3-piperidine, 4-piperidine, 5-piperidine, 6-piperidine), piperazine (1-piperazine, 2-piperazine, 3-piperazine, 4-piperazine, 5-piperazine, 6-piperazine), morpholine (2-morpholine, 3-morpholine, 4-morpholine, 5-morpholine, 6-morpholine), thiomorpholine (2-thiomorpholine, 3-thiomorpholine, 4-thiomorpholine, 5-thiomorpholine, 6-thiomorpholine), 1,2-oxathiolane (3-(1,2-oxathiolane), 4-(1,2-oxathiolane), 5-(1,2-oxathiolane)), 1,3-dioxolane (2-(1,3-dioxolane), 3-(1,3-dioxolane), 4-(1,3-dioxolane)), tetrahydropyran (2-tetrahydropyran, 3-tetrahydropyran, 4-tetrahydropyran, 5-tetrahydropyran, 6-tetrahydropyran), hexahydropyridazine, (1-hexahydropyridazine), 2-(hexahydropyridazine), 3-(hexahydropyridazine), 4-(hexahydropyridazine), 5-(hexahydropyridazine), 6-(hexahydropyridazine)).

The term "C₁₋₆alkyl-C₃₋₁₀cycloalkyl" as used herein refers to a cycloalkyl group as defined above attached through an alkyl group as defined above having the indicated number of carbon atoms.

The term "C₁₋₆alkyl-C₃₋₇heterocycloalkyl" as used herein refers to a heterocycloalkyl group as defined above attached through an alkyl group as defined above having the indicated number of carbon atoms.

The term "aryl" as used herein is intended to include carbocyclic aromatic ring systems. Aryl is also intended to include the partially hydrogenated derivatives of the carbocyclic systems enumerated below. Non-limiting examples of such partially hydrogenated derivatives are 1,2,3,4-tetrahydronaphthyl, 1,4-dihydronaphthyl and the like.

The term "heteroaryl" as used herein includes heterocyclic unsaturated ring systems containing one or more heteroatoms selected among nitrogen, oxygen and sulphur, such as furyl, thienyl, pyrrolyl, and is also intended to include the partially hydrogenated derivatives of the heterocyclic systems enumerated below. Non-limiting examples of such partially hydrogenated derivatives are 2,3-dihydrobenzofuranyl, pyrrolinyl, pyrazolinyl, indolinyl, oxazolidinyl, oxazolinyl, oxazepinyl and the like.

The terms "aryl" and "heteroaryl" as used herein refers to an aryl, which can be optionally mono-, di- or tri-substituted, or a heteroaryl, which can be optionally mono-, di- or tri-substituted. Examples of useful substituents are: halogen, hydroxy, amino, mercapto, nitro, cyano, trifluoromethyl, C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆alkylthio, C₁₋₆alkylamino, alkylamino-C₁₋₆alkyl and dialkylamino-C₁₋₆alkyl. Examples include, but are not limited to, phenyl, biphenyl, indenyl, naphthyl (1-naphthyl, 2-naphthyl), N-hydroxytetrazolyl, N-

72703-dk01

5

- hydroxytriazolyl, N-hydroxyimidazolyl, anthracenyl (1-anthracenyl, 2-anthracenyl, 3-anthracenyl), phenanthrenyl, fluorenyl, pentalenyl, azulcnyl, biphenylenyl, thiophenyl (1-thienyl, 2-thienyl), furyl (1-furyl, 2-furyl), furanyl, thiophenyl, isoxazolyl, isothiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, pyranyl, pyridazinyl, pyrazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, tetrazolyl, thiadiazinyl, indolyl, isoindolyl, benzofuranyl, benzothiophenyl (thianaphthenyl), indolyl, oxadiazolyl, isoxazolyl, quinazolinyl, fluorenyl, xanthenyl, isoindanyl, benzhydryl, acridinyl, benzisoxazolyl, purinyl, quinazolinyl, quinoliziny, quinoliny, isoquinoliny, quinoxaliny, naphthyridinyl, phteridinyl, azepinyl, diazepinyl, pyrrolyl (2-pyrrolyl), pyrazolyl (3-pyrazolyl), imidazolyl (1-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl), triazolyl (1,2,3-triazol-1-yl, 1,2,3-triazol-2-yl, 1,2,3-triazol-4-yl, 1,2,4-triazol-3-yl), oxazolyl (2-oxazolyl, 4-oxazolyl, 5-oxazolyl), thiazolyl (2-thiazolyl, 4-thiazolyl, 5-thiazolyl), pyridyl (2-pyridyl, 3-pyridyl, 4-pyridyl), pyrimidinyl (2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 6-pyrimidinyl), pyrazinyl, pyridazinyl (3-pyridazinyl, 4-pyridazinyl, 5-pyridazinyl), isoquinolyl (1-isoquinolyl, 3-isoquinolyl, 4-isoquinolyl, 5-isoquinolyl, 6-isoquinolyl, 7-isoquinolyl, 8-isoquinolyl), quinolyl (2-quinolyl, 3-quinolyl, 4-quinolyl, 5-quinolyl, 6-quinolyl, 7-quinolyl, 8-quinolyl), benzo[b]furanyl (2-benzo[b]furanyl, 3-benzo[b]furanyl, 4-benzo[b]furanyl, 5-benzo[b]furanyl, 6-benzo[b]furanyl, 7-benzo[b]furanyl), 2,3-dihydro-benzo[b]furanyl (2-(2,3-dihydro-benzo[b]furanyl), 3-(2,3-dihydro-benzo[b]furanyl), 4-(2,3-dihydro-benzo[b]furanyl), 5-(2,3-dihydro-benzo[b]furanyl), 6-(2,3-dihydro-benzo[b]furanyl), 7-(2,3-dihydro-benzo[b]furanyl)), benzo[b]thiophenyl (2-benzo[b]thiophenyl, 3-benzo[b]thiophenyl, 4-benzo[b]thiophenyl, 5-benzo[b]thiophenyl, 6-benzo[b]thiophenyl, 7-benzo[b]thiophenyl), 2,3-dihydro-benzo[b]thiophenyl (2-(2,3-dihydro-benzo[b]thiophenyl), 3-(2,3-dihydro-benzo[b]thiophenyl), 4-(2,3-dihydro-benzo[b]thiophenyl), 5-(2,3-dihydro-benzo[b]thiophenyl), 6-(2,3-dihydro-benzo[b]thiophenyl), 7-(2,3-dihydro-benzo[b]thiophenyl)), indolyl (1-indolyl, 2-indolyl, 3-indolyl, 4-indolyl, 5-indolyl, 6-indolyl, 7-indolyl), indazolyl (1-indazolyl, 2-indazolyl, 3-indazolyl, 4-indazolyl, 5-indazolyl, 6-indazolyl, 7-indazolyl), benzimidazolyl (1-benzimidazolyl, 2-benzimidazolyl, 4-benzimidazolyl, 5-benzimidazolyl, 6-benzimidazolyl, 7-benzimidazolyl, 8-benzimidazolyl), benzoxazolyl (1-benzoxazolyl, 2-benzoxazolyl), benzothiazolyl (1-benzothiazolyl, 2-benzothiazolyl, 4-benzothiazolyl, 5-benzothiazolyl, 6-benzothiazolyl, 7-benzothiazolyl), carbazolyl (1-carbazolyl, 2-carbazolyl, 3-carbazolyl, 4-carbazolyl).

72703-dk01

6

The term "C₁₋₆ alkylaryl" as used herein refers to an aryl group as defined above attached through a C₁₋₆ alkyl group as defined above having one, two, three, four, five or six carbon atoms; it is to be understood that the term includes unsubstituted or substituted C₁₋₆ alkylaryl.

- 5 The term "C₁₋₆ alkylheteroaryl" as used herein refers to a heteroaryl group as defined above attached through a C₁₋₆ alkyl group as defined above having one, two, three, four, five or six carbon atoms; it is to be understood that the term includes unsubstituted or substituted C₁₋₆ alkylheteroaryl.

- 10 The term "C₁₋₆-alkylthio" in the present context designates a group -S-C₁₋₆-alkyl wherein C₁₋₆-alkyl is as defined above. Representative examples include, but are not limited to, methylthio, ethylthio, n-propylthio, isopropylthio, butylthio, isobutylthio, sec-butylthio, tert-butylthio, n-pentylthio, isopentylthio, neopentylthio, tert-pentylthio, n-hexylthio, isohexylthio and the like.

- 15 The term "C₁₋₆-alkylmercapto" in the present context designates a group -SH-C₁₋₆-alkyl wherein C₁₋₆-alkyl is as defined above. Representative examples include, but are not limited to, methylmercapto, ethylmercapto, n-propylmercapto, isopropylmercapto, butylmercapto, isobutylmercapto, sec-butylmercapto, tert-butylmercapto, n-pentylmercapto, isopentylmercapto, neopentylmercapto, tert-pentylmercapto, n-hexylmercapto, isohexylmercapto and the like.

- 20 The term "C₁₋₆-alkylhydroxy" in the present context designates a group -OH-C₁₋₆-alkyl wherein C₁₋₆-alkyl is as defined above. Representative examples include, but are not limited to, methylhydroxy, ethylhydroxy, n-propylhydroxy, isopropylhydroxy, butylhydroxy, isobutylhydroxy, sec-butylhydroxy, tert-butylhydroxy, n-pentylhydroxy, isopentylhydroxy, neopentylhydroxy, tert-pentylhydroxy, n-hexylhydroxy, isohexylhydroxy and the like.

- 25 The term "C₁₋₆-alkylamino" in the present context designates a group -NH-C₁₋₆-alkyl wherein C₁₋₆-alkyl is as defined above. Representative examples include, but are not limited to, methylamino, ethylamino, n-propylamino, isopropylamino, butylamino, isobutylamino, sec-butylamino, tert-butylamino, n-pentylamino, isopentylamino, neopentylamino, tert-pentylamino, n-hexylamino, isohexylamino and the like.

- 30 The term "alkylamino-C₁₋₆-alkyl" in the present context designates a group C₁₋₆-alkyl -NH-C₁₋₆-alkyl wherein C₁₋₆-alkyl is as defined above. Representative examples include, but are not limited to, methylamino methyl, ethylamino methyl, n-propylamino methyl, isopropylamino methyl, butylamino methyl, isobutylamino methyl, sec-butylamino methyl, tert-butylamino methyl, n-pentylamino methyl, isopentylamino methyl, neopentylamino

72703-dk01

7

methyl, tert-pentylamino methyl, n-hexylamino methyl, isohexylamino methyl, methylamino ethyl, methylamino propyl, methylamino isopropyl, methylamino butyl, methylamino isobutyl, methylamino pentyl, methylamino isopentyl, methylamino hexyl, methylamino isohexyl and the like.

- 5 The term "dialkylamino-C₁₋₆-alkyl" in the present context designates a group (C₁₋₆-alkyl)₂-N-C₁₋₆-alkyl wherein C₁₋₆-alkyl is as defined above. Representative examples include, but are not limited to, dimethylamino methyl, diethylamino methyl, dipropylamino methyl, di-isopropylamino methyl, dibutylamino methyl, di-isobutylamino methyl, di-sec-butylamino methyl, di-tert-butylamino methyl, dipentylamino methyl, di-isopentylamino methyl, di-neopentylamino methyl, di-tert-pentylamino methyl, dihexylamino methyl, diisohexylamino methyl, dimethylamino ethyl, dimethylamino propyl, dimethylamino isopropyl, dimethylamino butyl, dimethylamino isobutyl, dimethylamino pentyl, dimethylamino isopentyl, dimethylamino hexyl, dimethylamino isohexyl and the like.

"Halogen" designates an atom selected from the group consisting of F, Cl, Br and I.

- 15 The term "optionally substituted" as used herein means that the groups in question are either unsubstituted or substituted with one or more of the substituents specified or substituted with one or more, for example one, two, three or four, substituents selected from halogen, hydroxy, amino, mercapto, nitro, cyano, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆alkylthio, C₁₋₆alkylamino, alkylamino-C₁₋₆alkyl and dialkylamino-C₁₋₆alkyl. When the groups in question are substituted with more than one substituent the substituents may be the same or different.

Certain of the above defined terms may occur more than once in the structural formulae, and upon such occurrence each term shall be defined independently of the other.

- 25 As used herein, the phrase "a functional group which can be converted to hydrogen in vivo" is intended to include any group which upon administering the present compounds to the subjects in need thereof can be converted to hydrogen eg enzymatically or by the acidic environment in the stomach. Non-limiting examples of such groups are acyl, carbamoyl, monoalkylated carbamoyl, dialkylated carbamoyl, alkoxycarbonyl, alkoxyalkyl groups and the like such as C₁₋₆-alkylcarbonyl, aroyl, C₁₋₆-alkylcarbamoyl, di-C₁₋₆ alkyl-alkylcarbamoyl, C₁₋₆-alkoxycarbonyl and C₁₋₆-alkoxy-C₁₋₆-alkyl.

30 As used herein, the phrase "diseases and disorders related to peptide deformylase" is intended to include any disease or disorder in which an effect, preferably an inhibiting effect, on peptide deformylase is beneficial, especially on the bacterial peptide deformylase.

72703-dk01

8

The term "IC₅₀" as used herein denotes the concentration required for 50% inhibition of PDF in a binding assay.


Abbreviations and symbols commonly used in the peptide and chemical arts are used herein to describe the compounds of the present invention. In general, the amino acid
5 abbreviations follow the IUPAC-IUB Joint Commission on Biochemical Nomenclature as described in Eur. J. Biochem., 158, 9 (1984).

Certain radical groups are abbreviated herein. t-Bu refers to the tertiary butyl radical, Boc refers to the t-butyloxycarbonyl radical, Fmoc refers to the fluorenylmethoxycarbonyl radical, Ph refers to the phenyl radical, Cbz refers to the benzyloxycarbonyl radical.

10

The compounds

The present invention relates to compounds of the general formula (I)



15

or a pharmaceutically acceptable salt or ester thereof, wherein

X is -CONHOH, -COOH or -N(OH)COH;

n is 0 (zero) or an integer 1 or 2;

m is an integer 1, 2, 3 or 4;

20 R₁ is selected from the group consisting of hydrogen, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₃₋₁₀ cycloalkyl, C₁₋₆ alkyl-C₃₋₁₀ cycloalkyl, C₃₋₇ heterocycloalkyl, C₁₋₆ alkoxy, C₁₋₆ alkylamino, C₁₋₆ alkylmercapto, C₁₋₆ alkylhydroxy, C₁₋₆ alkylthio, alkylamino-C₁₋₆alkyl, dialkylamino-C₁₋₆alkyl; and any aryl, heteroaryl, C₁₋₆ alkylaryl or C₁₋₆ alkylheteroaryl optionally substituted
25 mercapto, nitro, cyano, trifluoromethyl, C₁₋₆ alkyl, C₁₋₆ alkoxy and C₁₋₆ alkylthio;

one of R₂ and R₃ is selected from the group consisting of halogen, hydrogen, carboxylic acid, -CONR₄R₅ and -CONHR₃, in which R₄ and R₅ are identical or different and independently of
30 each other are selected from the group consisting of C₃₋₇ heterocycloalkyl and any of C₁₋₆ alkyl-C₃₋₇ heterocycloalkyl, aryl, heteroaryl, C₁₋₆ alkylaryl and C₁₋₆ alkylheteroaryl optionally substituted with one or more substituents independently selected from halogen, hydroxy, amino, mercapto, nitro, cyano, trifluoromethyl, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkylthio, C₁₋₆ alkylhydroxy, C₁₋₆ alkylamino, alkylamino-C₁₋₆alkyl and dialkylamino-C₁₋₆alkyl; and

72703-dk01

9

the other of R_2 and R_3 is selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-10} cycloalkyl, C_{1-6} alkyl- C_{3-10} cycloalkyl, C_{3-7} heterocycloalkyl, C_{1-6} alkoxy, C_{1-6} alkylamino, C_{1-6} alkylmercapto, C_{1-6} alkylhydroxy, C_{1-6} alkylthio, alkylamino- C_{1-6} alkyl, dialkylamino- C_{1-6} alkyl; and any aryl, heteroaryl, C_{1-6} alkylaryl or C_{1-6} alkylheteroaryl optionally substituted with one or more substituents independently selected from halogen, hydroxy, amino, mercapto, nitro, cyano, trifluoromethyl, C_{1-6} alkyl, C_{1-6} alkoxy and C_{1-6} alkylthio.

In a preferred embodiment of the invention, X is $-\text{CONHOH}$. However, in other useful embodiments of the invention, X is $-\text{COOH}$ or $-\text{N(OH)COH}$.

In a preferred embodiment of the invention, n is 2. However, in other useful embodiments of the invention, n is 0 or n is 1, preferably 0.

In a preferred embodiment of the invention, m is 1. However, in other useful embodiments of the invention, n is 2, 3 or 4.

Preferably, R_1 is selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{3-10} cycloalkyl, C_{1-6} alkyl- C_{3-10} cycloalkyl, C_{1-6} alkylamino, C_{1-6} alkylhydroxy; and any C_{1-6} alkylaryl or C_{1-6} alkylheteroaryl optionally substituted with one or more substituents independently selected from halogen, hydroxy, amino, mercapto, nitro, cyano, trifluoromethyl, C_{1-6} alkyl, C_{1-6} alkoxy, and C_{1-6} alkylthio. More preferably, R_1 is selected from hydrogen, methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, methyl cyclopropyl, methyl cyclobutyl, methyl cyclohexyl, ethyl cyclohexyl, ethylamino, propylamino, butylamino, methylhydroxy, ethylhydroxy, propylhydroxy, butylhydroxy, phenyl, benzyl, fluorosubstituted phenyl, fluorosubstituted benzyl, chlorosubstituted phenyl, chlorosubstituted benzyl, bromo substituted phenyl and bromo substituted benzyl; especially from hydrogen, methyl, ethyl, propyl, butyl, pentyl, methylcyclopropyl, methylcyclobutyl, methylcyclopentyl, methylcyclohexyl, methylphenyl and methyl-3-fluorophenyl.

In a preferred embodiment of the present invention, one of R_2/R_3 is selected among hydrogen, fluorine, chlorine, bromine, iodine and carboxylic acid.

In another preferred embodiment of the present invention, one of R_2/R_3 is $-\text{CONHR}_5$ or $-\text{CONR}_4\text{R}_5$:



In yet another preferred embodiment of the present invention, one of R_2/R_3 is selected among C_{3-7} heterocycloalkyl; and aryl, heteroaryl, C_{1-6} alkylaryl or C_{1-6} alkylheteroaryl

72703-uk01

10

optionally substituted with one or more substituents independently selected from halogen, hydroxy, amino, mercapto, nitro, cyano, trifluoromethyl, C₁₋₆ alkyl, C₁₋₆ alkoxy and C₁₋₆ alkylthio.

- Most preferably, one of R₂/R₃ is hydrogen, C₃₋₇ heterocycloalkyl or C₃₋₇ heterocycloalkyl; especially hydrogen or 1-piperazinyl.

- When one of R₂/R₃ is -CONHR₅ or -CONR₄R₅, R₄ or R₅ is independently of each other preferably C₃₋₇ heterocycloalkyl, C₁₋₆ alkyl-C₃₋₇ heterocycloalkyl, heteroaryl or C₁₋₆ alkylheteroaryl having one or more heteroatoms selected among N, O and S; or aryl, heteroaryl, C₁₋₆ alkylaryl or C₁₋₆ alkylheteroaryl, any of which may be substituted with one or more substituents independently selected from halogen, hydroxy, amino, mercapto, nitro, cyano, trifluoromethyl, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkylthio, C₁₋₆ alkylhydroxy, C₁₋₆ alkylamino, alkylamino-C₁₋₆alkyl and dialkylamino-C₁₋₆alkyl.

- More preferably, R₄ or R₅ is independently selected from a group consisting of benzyl; mono-, di-, tri- or tetra-fluoro-substituted benzyl, mono-, di-, tri- or tetra-bromo-substituted benzyl, trifluoromethyl substituted benzyl, trifluoromethoxy substituted benzyl, dimethylamino substituted benzyl, nitro substituted benzyl, 5-thiophen-2-yl-2H-pyrazol-3-yl, 8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl, methylpyridyl, methyl-2-thienyl, 3-pyrazolyl, 2-thiazolyl, 4-methyl-1-piperazinyl.

- Preferred compounds of the invention are:

- 2-(3,4-Dihydro-2H-benzo[1,4]thiazin-2-yl)-N-hydroxy-acetamide
2-(1,1-Dioxo-1,2,3,4-tetrahydro-1 λ⁶-benzo[1,4]thiazin-2-yl)-N-hydroxy-acetamide
2-(4-Ethyl-3,4-dihydro-2H-benzo[1,4]thiazin-2-yl)-N-hydroxy-acetamide
25 2-(4-Ethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ⁶-benzo[1,4]thiazin-2-yl)-N-hydroxy-acetamide
N-Hydroxy-2-(4-propyl-3,4-dihydro-2H-benzo[1,4]thiazin-2-yl)-acetamide
2-(1,1-Dioxo-4-propyl-1,2,3,4-tetrahydro-1 λ⁶-benzo[1,4]thiazin-2-yl)-N-hydroxy-acetamide
2-(4-Butyl-3,4-dihydro-2H-benzo[1,4]thiazin-2-yl)-N-hydroxy-acetamide
2-(4-Butyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ⁶-benzo[1,4]thiazin-2-yl)-N-hydroxy-acetamide
30 2-(4-Benzyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ⁶-benzo[1,4]thiazin-2-yl)-N-hydroxy-acetamide
2-[4-(3-Fluoro-benzyl)-1,1-dioxo-1,2,3,4-tetrahydro-1 λ⁶-benzo[1,4]thiazin-2-yl]-N-hydroxy-acetamide

72703-dk01

11

- 4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid benzylamide
- 4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid 2-fluoro-benzylamide
- 5 4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid 3-fluoro-benzylamide
- 4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid 4-fluoro-benzylamide
- 4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid 2-bromo-benzylamide
- 10 4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid 3-bromo-benzylamide
- 4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid 4-bromo-benzylamide
- 15 4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid 2-nitro-benzylamide
- 4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid 3-nitro-benzylamide
- 4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid 4-nitro-benzylamide
- 20 4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid 2-methoxy-benzylamide
- 4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid 3-methoxy-benzylamide
- 25 4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid 4-methoxy-benzylamide
- 4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid 3-trifluoromethyl-benzylamide
- 4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid 4-trifluoromethyl-benzylamide
- 30 4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid 4-trifluoromethoxybenzylamide

72703-dk01

12

- 4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid 4-dimethylaminobenzylamide
- 4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid (pyridin-4-ylmethyl)-amide
- 5 4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid (thiophen-2-ylmethyl)-amide
- 4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid (1H-pyrazol-3-yl)-amide
- 4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid thiazol-2-ylamide
- 10 2-[4-Ethyl-6-(4-methyl-piperazine-1-carbonyl)-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazin-2-yl]-N-hydroxy-acetamide
- 4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid (5-thiophen-2-yl-2H-pyrazol-3-yl)-amide
- 15 4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide
- 2-(4-Cyclopropylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazin-2-yl)-N-hydroxy-acetamide
- 2-(4-Cyclobutylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazin-2-yl)-N-hydroxy-acetamide
- 20 2-(4-Cyclopentylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazin-2-yl)-N-hydroxy-acetamide, and
- 2-(4-Cyclohexylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazin-2-yl)-N-hydroxy-acetamide.

25

The compounds of the invention may exist as geometric isomers or optical isomers or stereoisomers as well as tautomers. Accordingly, the invention includes all geometric isomers and tautomers including mixtures and racemic mixtures of these and a pharmaceutically acceptable salt thereof, especially all *R*- and *S*- isomers. The compounds of the invention may

30 also exist as solvent complexes as well as in different morphological forms.

The present invention also encompasses pharmaceutically acceptable salts of the present compounds. Such salts include pharmaceutically acceptable acid addition salts, pharmaceutically acceptable metal salts, ammonium and alkylated ammonium salts. Acid

72703-dk01

13

addition salts include salts of inorganic acids as well as organic acids. Representative examples of suitable inorganic acids include hydrochloric, hydrobromic, hydroiodic, phosphoric, sulfuric, nitric acids and the like. Representative examples of suitable organic acids include formic, acetic, trichloroacetic, trifluoroacetic, propionic, benzoic, cinnamic, citric, fumaric, glycolic, lactic, maleic, malic, malonic, mandelic, oxalic, picric, pyruvic, salicylic, succinic, methanesulfonic, ethanesulfonic, tartaric, ascorbic, pantoic, bismethylene salicylic, ethanedisulfonic, gluconic, citraconic, aspartic, stearic, palmitic, EDTA, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, p-toluenesulfonic acids and the like. Further examples of pharmaceutically acceptable inorganic or organic acid addition salts include the pharmaceutically acceptable salts listed in *J. Pharm. Sci.* 1977, 66, 2, which is incorporated herein by reference. Examples of metal salts include lithium, sodium, potassium, magnesium salts and the like. Examples of ammonium and alkylated ammonium salts include ammonium, methylammonium, dimethylammonium, trimethylammonium, ethylammonium, hydroxyethylammonium, diethylammonium, butylammonium, tetramethylammonium salts and the like.

Also intended as pharmaceutically acceptable acid addition salts are the hydrates and solvent complexes, which the present compounds are able to form.

The acid addition salts may be obtained as the direct products of compound synthesis. In the alternative, the free base may be dissolved in a suitable solvent containing the appropriate acid, and the salt isolated by evaporating the solvent or otherwise separating the salt and solvent.

The compounds of the present invention may form solvates with standard low molecular weight solvents using methods well known to the person skilled in the art. Such solvates are also contemplated as being within the scope of the present invention.

The invention also encompasses prodrugs of the present compounds, which on administration undergo chemical conversion by metabolic processes before becoming active pharmacological substances. In general, such prodrugs will be functional derivatives of the present compounds, which are readily convertible in vivo into the required compound of the Formula I. Prodrugs are any covalently bonded compounds, which release the active parent drug according to Formula I in vivo. If a chiral center or another form of an isomeric center is present in a compound of the present invention, all forms of such isomer or isomers, including enantiomers and diastereomers, are intended to be covered herein. Inventive compounds containing a chiral center may be used as a racemic mixture, an enantiomerically enriched mixture, or the racemic mixture may be separated using well-known techniques and

72703-dk01

14

an individual enantiomer may be used alone. In cases wherein compounds may exist in tautomeric forms, such as keto-enol tautomers, each tautomeric form is contemplated as being included within this invention whether existing in equilibrium or predominantly in one form. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985.

The invention also encompasses active metabolites of the present compounds.

The present invention includes all complexes of the compounds of this invention.

The meaning of any substituent at any one occurrence in Formula I or any subformula thereof is independent of its meaning, or any other substituent's meaning, at any other occurrence, unless specified otherwise.

In a preferred embodiment of this invention, the compounds of Formula I exhibit an IC_{50} value of less than 500 μ M, preferably less than 100 μ M, more preferably less than 50 μ M, even more preferably less than 1 μ M, especially less than 500 nM, particularly less than 100 nM, when subjected to a bacterial PDF assay.

Synthetic Method of Preparation

The compounds of the present invention having the general Formula I may be prepared by the methods set forth in the scheme A, B, C and D in 'Materials and Method' below.

The compounds in scheme A can be synthesized as depicted. The amino thiol is first acylated and consecutive Michael addition n (step 1) to yield intermediate (I). Intermediate (I) is then esterified in step 2 to give intermediate (II). The intermediate (II) is reduced (step 3) using borane. Acylation of (III) in step 4 using the appropriate acid chlorides gives intermediates (IV). Oxidation of intermediates (IV) using sodium perborate (to give intermediate (V)). The reaction time was 14-16 h. Reduction of the reaction time to a couple of hours resulted in mono-oxidation of the sulphur and hence title compounds having n = 1 as a result), reduction (in step 6) using borane (to give intermediates (VI)) and finally hydrolysis using hydroxylamine (step 7) gave the desired products (VII) of scheme A.

The compound in scheme B can be synthesized as depicted. Intermediate (III) in scheme A was oxidised in step 1 to give intermediate (IV). Hydrolysis of the ester functionality with hydroxylamine (step 2) ultimately yielded the desired product (V) of scheme B.

72703-dk01

15

The compounds in scheme C can be synthesized as depicted. Intermediate (III) in scheme C was reduced using borane to give intermediate (IV), which upon hydrolysis with hydroxylamine yielded the desired products (V) of scheme C.

5 The compounds in scheme D can be synthesized as depicted. The acid chloride was esterified using fluorenyl methanol (step 1) to give intermediate (I). Nucleophilic aromatic addition of (II) to (I) in step 2 using Hünig's base resulted in intermediate (III). Reduction of the amino functionality (step 3) and subsequent ring closure of intermediate (III) gave (IV). Reduction in step 4 using borane and thereafter acetylation in step 5 resulted in intermediate (VI). Oxidation (step 6) using sodium perborate and reduction (step 7) using borane gave
10 intermediate (VIII). Deprotection of the acid functionality (step 8) using diethylamine gave intermediate (X), which was used to create the amide library in the following reaction steps using the appropriate amine, TBTU and NEM (step 9). Hydrolysis using hydroxylamine in step 10 gave the desired amides (XI) of scheme D.

The compound in scheme E can be synthesized as depicted: The trifluoronitro
15 benzene was reacted with the Fmoc-protected piperazine to give the product after step 1 as a result. The rest of the synthesis was carried out analogous to method D (scheme D).

Acid addition salts of the compounds of Formula I are prepared in a standard manner in a suitable solvent from the parent compound and an excess of an acid, such as
20 hydrochloric, hydrobromic, hydrofluoric, sulfuric, phosphoric, acetic, trifluoroacetic, maleic, succinic or methanesulfonic. Certain of the compounds form inner salts or zwitterions, which may be acceptable. Cationic salts are prepared by treating the parent compound with an excess of an alkaline reagent, such as a hydroxide, carbonate or alkoxide, containing the appropriate cation; or with an appropriate organic amine. Cations such as Li^+ , Na^+ , K^+ , Ca^{++} ,
25 Mg^{++} and NH_4^+ are specific examples of cations present in pharmaceutically acceptable salts. Halides, sulfate, phosphate, alkanoates (such as acetate and trifluoroacetate), benzoates, and sulfonates (such as mesylate) are examples of anions present in pharmaceutically acceptable salts.

30 Pharmaceutical compositions

In one aspect of this invention, there is provided a pharmaceutical composition comprising, as an active ingredient, a compound of the present invention together with a pharmaceutically acceptable carrier or diluent. This composition may be in unit dosage form and may comprise from about 0.05 to about 500 mg, preferably from about 0.05 to about 100

72703-dk01

16

mg, more preferably from about 0.1 to about 50 mg, of the compound of the invention or a pharmaceutically acceptable salt or ester thereof. The composition of the invention may be used for oral, nasal, transdermal, pulmonal or parenteral administration. It is contemplated that the pharmaceutical composition of the invention is useful for treatment of bacterial
5 and/or parasitic infections.

The compounds of the invention may be administered alone or in combination with pharmaceutically acceptable carriers, diluents or excipients, in either single or multiple doses. Accordingly, the compounds of Formula I may be used in the manufacture of a medicament. The pharmaceutical compositions according to the invention may be formulated with
10 pharmaceutically acceptable carriers or diluents as well as any other known adjuvants and excipients in accordance with conventional techniques such as those disclosed in Remington: The Science and Practice of Pharmacy, 19th Edition, Gennaro, Ed., Mack Publishing Co., Easton, Pa., 1995.

The pharmaceutical compositions may be specifically formulated for administration
15 by any suitable route such as the oral, rectal, nasal, pulmonary, topical (including buccal and sublingual), transdermal, intracisternal, intraperitoneal, vaginal and parenteral (including subcutaneous, intramuscular, intrathecal, intravenous and intradermal) route, the oral route being preferred. It will be appreciated that the preferred route will depend on the general condition and age of the subject to be treated, the nature of the condition to be treated and the
20 active ingredient chosen.

Pharmaceutical compositions for oral administration include solid dosage forms such as capsules, tablets, dragees, pills, lozenges, powders and granules. Where appropriate, they can be prepared with coatings such as enteric coatings or they can be formulated so as to provide controlled release of the active ingredient such as sustained or prolonged release
25 according to methods well known in the art.

Liquid dosage forms for oral administration include solutions, emulsions, suspensions, syrups and elixirs.

Pharmaceutical compositions for parenteral administration include sterile aqueous and non-aqueous injectable solutions, dispersions, suspensions or emulsions as well as sterile
30 powders to be reconstituted in sterile injectable solutions or dispersions prior to use. Depot injectable formulations are also contemplated as being within the scope of the present invention.

Other suitable administration forms include suppositories, sprays, ointments, cremes, gels, inhalants, dermal patches, implants etc.

72703-dk01

17

A typical oral dosage is in the range of from about 0.001 to about 50 mg/kg body weight per day, preferably from about 0.01 to about 30 mg/kg body weight per day, and more preferred from about 0.05 to about 20 mg/kg body weight per day administered in one or more dosages such as 1 to 3 dosages. The exact dosage will depend upon the frequency and mode of administration, the sex, age, weight and general condition of the subject treated, the nature and severity of the condition treated and any concomitant diseases to be treated and other factors evident to those skilled in the art.

The formulations may conveniently be presented in unit dosage form by methods known to those skilled in the art. A typical unit dosage form for oral administration one or more times per day such as 1 to 3 times per day may contain from about 0.05 to about 500 mg, preferably from about 0.05 to about 100 mg, more preferably from about 0.1 to about 50 mg, and more preferred from about 0.5 mg to about 20 mg.

For parenteral routes, such as intravenous, intrathecal, intramuscular and similar administration, typically doses are in the order of about half the dose employed for oral administration.

The compounds of this invention are generally utilized as the free substance or as a pharmaceutically acceptable salt thereof. One example is an acid addition salt of a compound having the utility of a free base. When a compound of the Formula (I) contains a free base such salts are prepared in a conventional manner by treating a solution or suspension of a free base of the Formula (I) with a chemical equivalent of a pharmaceutically acceptable acid, for example, inorganic and organic acids. Representative examples are mentioned above. Physiologically acceptable salts of a compound with a hydroxy group include the anion of said compound in combination with a suitable cation such as sodium or ammonium ion. For parenteral administration, solutions of the novel compounds of the Formula (I) in sterile aqueous solution, aqueous propylene glycol or sesame or peanut oil may be employed. Such aqueous solutions should be suitable buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. The aqueous solutions are particularly suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. The sterile aqueous media employed are all readily available by standard techniques known to those skilled in the art.

Suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solution and various organic solvents. Examples of solid carriers are lactose, terra alba, sucrose, cyclodextrin, talc, gelatine, agar, pectin, acacia, magnesium stearate, stearic acid or lower alkyl ethers of cellulose. Examples of liquid carriers are syrup, peanut oil, olive oil,

72703-dk01

18

phospholipids, fatty acids, fatty acid amines, polyoxyethylene or water. Similarly, the carrier or diluent may include any sustained release material known in the art, such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax. The pharmaceutical compositions formed by combining the novel compounds of the Formula (I) and the pharmaceutically acceptable carriers are then readily administered in a variety of dosage forms suitable for the disclosed routes of administration. The formulations may conveniently be presented in unit dosage form by methods known in the art of pharmacy.

Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules or tablets, each containing a predetermined amount of the active ingredient, and which may include a suitable excipient. These formulations may be in the form of powder or granules, as a solution or suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion. If a solid carrier is used for oral administration, the preparation may be tableted, placed in a hard gelatine capsule in powder or pellet form or it can be in the form of a troche or lozenge. The amount of solid carrier will vary widely but will usually be from about 25 mg to about 1 g. If a liquid carrier is used, the preparation may be in the form of a syrup, emulsion, soft gelatine capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution.

A typical tablet, which may be prepared by conventional tableting techniques, may contain:

Core:

Active compound (free compound or salt)	5.0 mg
Lactosum Ph. Eur.	67.8 mg
Cellulose, microcryst. (Avicel)	31.4 mg
Amberlite	1.0 mg
Magnesium stearate	q.s.

Coating:

Hydroxypropyl methylcellulose approx.	9 mg
Acylated monoglyceride approx.	0.9 mg

If desired, the pharmaceutical composition of the invention may comprise the compound of the Formula (I) in combination with further pharmacologically active substances such as those described in the foregoing.

72703-dk01

19

Use of the invention

The compounds of Formula I are useful as protease inhibitors, particularly as inhibitors of metallo proteases, more particularly as inhibitors of peptide deformylase, even more particularly as inhibitors of bacterial peptide deformylase. The present invention provides
5 useful compositions and formulations of said compounds, including pharmaceutical compositions and formulations of said compounds.

The compounds of the present invention may be especially useful for the treatment or prevention of diseases caused by a variety of bacterial or prokaryotic organisms. Examples include Gram-positive and Gram-negative aerobic and anaerobic bacteria such as,
10 *Staphylococci*, for example *S. aureus* and *S. epidermidis*; *Enterococci*, for example *E. faecium* and *E. faecalis*; *Streptococci*, for example *S. pneumoniae*; *Haemophilus*, for example *H. influenzae*; *Moraxella*, for example *M. catarrhalis*; *Escherichia*, for example *E. coli*; *Mycobacteria*, for example *M. tuberculosis* and *M. ranue*; *Mycoplasma*, for example *M. pneumoniae*; *Pseudomonas*, for example *P. aeruginosa*; intercellular microbes, for example
15 *Chlamydia* and *Rickettsiae*. Other examples include *Klebsiella pneumoniae*, *Shigella flexneri*, *Salmonella typhimurium*, *Bordetella pertussis*, *Clostridia perfringens*, *Helicobacter pylori*, *Campylobacter jejuni*, *Legionella pneumophila* and *Neisseria gonorrhoeae*. It is further contemplated that the compounds of the present invention are useful for the treatment of parasitic infections, for example infections caused by *Plasmodium falciparum* and the like.

20 Accordingly, in one aspect the present invention relates to a method for the treatment of ailments, the method comprising administering to a subject in need thereof an effective amount of a compound or a composition of this invention. It is contemplated that an effective amount of a compound or a composition of this invention corresponds to an amount of active ingredient, i.e. active compound or a pharmaceutically acceptable salt or ester thereof, in the
25 range of from about 0.05 to about 100 mg per day, preferably from about 0.1 to about 50 mg per day.

In yet another aspect, the present invention relates to use of a compound of this invention for the preparation of a medicament, preferably a medicament for the treatment of infections caused by Gram-positive or Gram-negative aerobic or anaerobic bacteria, or by
30 parasites.

In a preferred embodiment of the invention, there is provided a medicament for the treatment of infections caused by *Staphylococci*, *Enterococci*, *Streptococci*, *Haemophilus*, *Moraxella*, *Escherichia*, *Mycobacteria*, *Mycoplasma*, *Pseudomonas*, *Chlamydia*, *Rickettsia*, *Klebsiella*, *Shigella*, *Salmonella*, *Bordetella*, *Clostridia*, *Helicobacter*, *Campylobacter*,

72703-dk01

20

Legionella and *Neisseria*, preferably caused by *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Enterococcus faecium*, *Enterococcus faecalis*, *Streptococcus pneumoniae*, *Haemophilus influenzae*, *Moraxella catarrhalis*, *Escherichia coli*, *Mycobacterium tuberculosis*, *Mycobacterium ranae*, *Mycoplasma pneumoniae*, *Pseudomonas aeruginosa*,
5 *Chlamydia*, *Rickettsiae*, *Klebsiella pneumoniae*, *Shigella flexneri*, *Salmonella typhimurium*,
Bordetella pertussis, *Clostridia perfringens*, *Helicobacter pylori*, *Campylobacter jejuni*,
Legionella pneumophila and *Neisseria gonorrhoeae*.

It is further contemplated that the compounds of the present invention are useful for the treatment of parasitic infections, for example infections caused by *Plasmodium*
10 *falciparum* and the like.

An intravenous infusion of the compound in 5% dextrose in water or normal saline, or a similar formulation with suitable excipients, is most effective, although an intramuscular bone injection is also useful. Typically, the parenteral dose will be about 0.01 to about 100
15 mg/kg; preferably between 0.1 and 20 mg/kg, in a manner to maintain the concentration of drug in the plasma at a concentration effective to inhibit PDF. The compounds may be administered one to four times daily at a level to achieve a total daily dose of about 0.4 to about 400 mg/kg/day. The precise amount of an inventive compound which is therapeutically effective, and the route by which such compound is best administered, is readily determined
20 by one of ordinary skill in the art by comparing the blood level of the agent to the concentration required to have a therapeutic effect.

The compounds of this invention may also be administered orally to the patient, in a manner such that the concentration of drug is sufficient to inhibit bone resorption or to achieve any other therapeutic indication as disclosed herein. Typically, a pharmaceutical
25 composition containing the compound is administered at an oral dose of between about 0.1 to about 50 mg/kg in a manner consistent with the condition of the patient. Preferably the oral dose would be about 0.5 to about 20 mg/kg.

No unacceptable toxicological effects are expected when compounds of the present invention are administered in accordance with the present invention.

30 The compounds of the present invention fully or partly inhibit bacterial PDF, and are thus useful for the treatment and/or prevention of a wide variety of conditions and disorders in which inhibition of PDF is beneficial.

Accordingly, in another aspect the present invention relates to a compound of the general Formula (I) or any optical or geometric isomer or tautomeric form thereof including

72703-dk01

21

mixtures of these or a pharmaceutically acceptable salt thereof for use as a pharmaceutical composition.

The invention also relates to pharmaceutical compositions comprising, as an active ingredient, at least one compound of the Formula (I) or any optical or geometric isomer or
5 tautomeric form thereof including mixtures of these or a pharmaceutically acceptable salt thereof together with one or more pharmaceutically acceptable carriers or diluents.

In the following synthetic examples, all of the starting materials were obtained from commercial sources unless otherwise indicated. Without further elaboration, it is believed
10 that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. These examples are given to illustrate the invention, not to limit its scope.

EXAMPLES

Materials and Methods

15 The starting materials used herein are commercially available or can be prepared according to procedures previously reported in the literature. Unless otherwise stated commercial starting materials were used without further purification. All solvents were HPLC grade. Anhydrous solvents were obtained by storing over 4 Å activated molecular
20 sieves. Synthetic methods to prepare the compounds of this invention might employ protective groups to mask a reactive functionality or minimize unwanted side reactions. Such protective groups are described generally in Green (1981).

Room temperature is approx. 20°C. Mass spectra (ES-MS spectra) were obtained on a Micromass Quattro microTM instrument in the positive mode unless otherwise noted.

25 Materials and abbreviations

AcOH	Acetic acid
DCM	Dichloromethane
DIEA	Diisopropylethyl amine
DMF	N,N-Dimethyl formamide
30 Fm	9-Fluorenylmethyl
Fmoc	9-Fluorenylmethoxycarbonyl
NEM	N-Ethyl morpholine (from Fluka; 98%)
TBTU	O-Benzotriazol-1-yl-N,N,N',N'-tetramethyluronium tetrafluoroborate (from Fluka; 98%)

72703-dk01

22


TFA Trifluoroacetic acid

THF Tetrahydrofuran

Piperidine was obtained from Fluka (98%). 1,2,4-Trifluoro-5-nitrobenzene was obtained from Aldrich (99%). 4-Chloro-3-nitrobenzoyl chloride obtained from Aldrich (98%). SnCl_2 was obtained from Fluka (98%). Maleic anhydride was obtained from Aldrich (95%). Thiomalic acid was obtained from Aldrich (97%). 9-Fluorenmethanol was obtained from Fluka (98%). Borane in THF (1M solution) was purchased from Aldrich. Hydroxylamine in water (50% solution) was purchased from Fluka. Sodium perborate tetrahydrate (97%) was purchased from Fluka. 1-Fmoc-piperazine hydrochloride was obtained from NeoSys (99%). 2-Aminothiophenol was obtained from Aldrich (99%). All used amines were obtained from Aldrich (purity 95-98%).

Synthesis of Compounds of the Invention

Illustrative general methods for the synthesis of the compounds of the invention are described below and illustrated in Scheme A, B, C, D and E respectively.



Scheme A

72703-dk01

23

Method A (Scheme A)

Step 1:

2-Aminothiophenol (120 mmol, 12.81 ml) was dissolved in toluene. Maleic anhydride (129 mmol, 12.6 g, 1.075 equiv.) was added to the solution. A precipitate was formed shortly after completion of addition of the maleic anhydride. The reaction was allowed to continue for another 3 hours at room temperature. The precipitate was collected and washed with several portions of toluene. Yield: 92%

Step 2:

The product from step 1 (I) (110 mmol, 24.5 g), was dissolved in methanol (acidified by addition of a few drops of acetyl chloride). The resulting solution was stirred at room temperature over night. The solvent was removed in vacuo to give (II) in scheme A. Yield: Quantitative.

Step 3:

The product from step 2 (II) (110 mmol, 26.5 g), was dissolved in dry THF, and cooled on an ice-bath under inert atmosphere (Ar). Borane in THF (132 mmol, 1M, 1.2 equiv) was added. After completion of addition of borane the ice-bath was removed and the reaction mixture was stirred over night at room temperature. The solvent was removed in vacuo. Water was added along with EtOAc. The organic phase was separated and the aqueous phase was extracted twice with EtOAc. The organic layers were combined and dried over Na₂SO₄. Removal of the organic phase yielded a yellow oil. The crude product was passed through a silica column using 50% EtOAc in heptane as eluent. Yield: 66%

Step 4:

The appropriate acyl chloride (1.1 equiv, typically 3.3 mmol) was dissolved in dry THF, and pyridine was added. A precipitate formed and a solution (in THF) of the product from step 3 (III) (typically 3.0 mmol, 0.67 g) was added. The resulting mixture was stirred at room temperature over night. The solvent was removed in vacuo. EtOAc was added and the resulting solution was washed with 1M HCl and there after with sat. NaHCO₃. The organic phase was dried over Na₂SO₄ and the solvent removed in vacuo. The product was used in the next step without further purification.

Step 5:

72703-dk01

24


The products formed in step 4 (IV) (typically 1.1-1.6 mmol) were dissolved in AcOH and NaBO₃ (4-5 equiv.) was added. The resulting solutions were heated to 50°C over night. The solvent was removed in vacuo, and the residues were partitioned between EtOAc and water. The organic phase was separated and dried over Na₂SO₄. The solvent was removed and the products were used without further purification.

Step 6:

The products from step 5 (V) were dissolved in dry THF and BH₃ in THF (1M, 1.2 equiv.) was added and the resulting solution was stirred at room temperature over night. The solvent was removed and sat. NaHCO₃ along with EtOAc was added. The organic phase was collected and dried over Na₂SO₄. The crude products were purified using preparative HPLC.

Step 7:

The products from step 6 (VI) (typically 0.4-0.1 mmol) were dissolved in dioxane and hydroxylamine (50% in water, typically 8-10 equiv.) was added. The resulting solution was heated to 50°C over night. The solutions were acidified (pH = 2) with TFA and purified by preparative HPLC to give the desired products (VIII).

20 Method B (Scheme B)

Scheme B

25 Step 1:


Intermediate (III) was synthesized in an identical manner to method A. Intermediate (III) (0.45 mmol, 100 mg) was dissolved in AcOH and NaBO₃ (5 equiv., 2.24 mmol, 345 mg). The procedure was then performed identical to step 5 in method A.

30 Step 2:

Intermediate (IV) was treated in an identical manner to method A, step 7 to yield (V).

72703-dk01

25

Method C (Scheme C)

Scheme C

For synthesis of (III), see method A.

Step 1:

10 Performed in an identical manner to method A, step 6.


Step 2:

Performed in an identical manner to method A, step 7.

Method D (Scheme D)

72703-dk01

26



Scheme D

5

Step 1:

4-Chloro-3-nitrobenzoyl chloride (1.13 equiv., 133.2 mmol, 29.3 g) was dissolved in dry THF and pyridine (2 equiv., 235.8 mmol, 19.0 ml) was added. A white precipitate formed immediately upon addition of pyridine. A solution of 9-fluorenemethanol (1 equiv., 117.9 mmol, 23.1 g) in dry THF was added and the resulting mixture was stirred at room

72703-dk01

27

temperature over night. The solvent was removed in vacuo and the resulting solid was mixed with diethyl ether and filtered. The solid was then washed several times with ether to achieve the pure desired product. Yield: 95%.

5 Step 2:

The intermediate from step 1 (I) (1 equiv., 60 mmol, 22.8 g) was dissolved in THF and a solution of dimethylthiomaleate (II) (1 equiv. 60 mmol, 10.4 g) in THF was added. To the resulting solution was added DIEA (1.2 equiv., 72 mmol, 12.3 ml). Upon addition of the base the solution turned into a deep orange colour. Stirring was continued at room
10 temperature over night. The solvent was removed and the resulting crude product was purified by column chromatography using 50% EtOAc in heptane as eluent. The pure product was retrieved as an orange oil. Yield: 88%

Step 3:

15 The product from step 2 (III) (1 equiv., 52.8 mmol, 27.5 g) was mixed with a solution of SnCl_2 (200 ml of a 2M solution). The resulting solution was stirred at room temperature over night. The solution had turned pale yellow after reduction of the nitro group. The solvent was removed in vacuo, and the crude product was passed through a short silica column using 50% EtOAc in chloroform as eluent. Removing the solvent produced an oil which was re-
20 dissolved in EtOAc and washed with water. The organic phase was removed and dried over Na_2SO_4 . Yield: Quantitative.

Step 4:

25 The product from step 3 (IV) (1 equiv., 60 mmol, 26.3 g) was dissolved in dry THF and BH_3 in THF (1M, 1.2 equiv, 72 mmol, 72 ml) was added. During addition of BH_3 the reaction solution was cooled on an ice-bath. The reaction solution was stirred at room temperature over night. The solvent was removed in vacuo and water and EtOAc was added to the solid residue. The organic phase was collected and the aqueous phase was extracted with EtOAc. The collected organic layers were combined and washed with brine. Drying
30 over Na_2SO_4 yielded a clear oil. Yield: 50%

Step 5:

The product from step 4 (V) (1 equiv., 11 mmol, 4.71 g) was dissolved in THF and acetyl chloride (3 equiv., 33 mmol, 2.3 ml) was added. Pyridine (4 equiv., 44 mmol, 3.5 ml)

72703-dk01

28

was added to the reaction solution. The resulting mixture was stirred at room temperature over night. The solvent was removed and the residue was partitioned between EtOAc and water. The organic phase was collected and washed with 1M HCl and water and finally with brine. Drying (over Na_2SO_4) and removal of the solvent yielded a brown oil. Yield: 91%.

5

Step 6:

The product from step 5 (IV) (1 equiv., 10mmol, 4.86 g) was dissolved in AcOH and NaBO_3 (5 equiv., 50 mmol, 7.7g) and the resulting mixture was warmed to 50°C over. The reaction was allowed to proceed over night at 50°C. The solvent was removed in vacuo and water along with EtOAc was added. The organic phase was collected and the aqueous phase was extracted with EtOAc. The combined organic phases were washed with water until the washings were of neutral pH. Drying and evaporation of the solvent resulted in a clear oil. Yield: 88%

15

Step 7:

The product from step 6 (VII) was treated in an identical manner as for step 4 using the identical ratio of reagent to substrate. Yield: 85%

Step 8:

The product from step 7 (VIII) (1 equiv., 11mmol, 5.6 g) was dissolved in DCM and diethylamine (3 equiv., 33 mmol, 3.4 ml) was added to the solution. Stirring was continued over night at reflux. The solvent was removed and the crude product was dissolved in NaOH (1M). The resulting solution was washed several times with ether and then acidified using 6M HCl. A pale yellow precipitate formed and was collected and allowed to dry under vacuum. The solid was chromatographed using 50% EtOAc in heptane containing 1% AcOH. Yield: 67%

25

Step 9:

The compound from step 8 (IX) (typically 1 equiv., 0.305 mmol, 100 mg) was dissolved in dry DMF (2.0 ml). To this solution was added NEM (4 equiv., 1.208 mmol, 0.154 ml) and TBTU (1 equiv., 0.305 mmol, 97 mg). The solution was left standing for 1h at room temperature. The appropriate amine (typically 1.2 equiv.) was added and the solution was left standing at room temperature over night. The solution was acidified with TFA and directly purified by preparative HPLC.

30

Step 10:

The compounds from step 9 (X) (typically 0.1-0.3 mmol) were dissolved in dioxane (1.0 ml) and hydroxylamine (50% in water, 0.25 ml) was added. The solutions were warmed to 50°C over night. The solutions were acidified with TFA and purified on preparative HPLC to yield the desired products (XI).

BIOLOGICAL ASSAYS

The compounds of this invention may be tested in the following biological assay in order to determine the concentration of compound (IC₅₀) required for exhibiting the desired pharmacological effect.

Bacterial peptide deformylase (PDF) assay

The IC₅₀ value of a compound of the invention as a bacterial PDF inhibitor was determined using the following assay.

Materials:

Assay buffer (pH 7.2): 0.1 M MOPS pH was adjusted to 7.2 with NaOH, containing 0.25 M NaCl, 100 microgram/mL catalase and 1 mg/mL BSA.

Enzyme mix: 670 ng/mL of enzyme (to finally have 50 ng of enzyme per well).

Substrate: 10 mM f-Met-Ala was made up from 200 mM f-Met-Ala in methanol with assay buffer.

TNBS solution: Freshly dilute 1 M TNBS stock solution to 1:10 with water.

Buffer C: 0.5 M borate buffer adjusted to pH 9.5 with NaOH.

Buffer D: 0.2 ml of freshly prepared 0.5 M Na₂SO₃ was mixed with 9.8 mL of 0.5M NaH₂PO₄.

Inhibitor solution: 2 mM Sodium 4-(hydroxymercurio) benzoate in assay buffer.

Method (Assay conditions):

The assay was performed in a 96 Microliter plate containing test compound. To each well containing test compound mix was added 75 microliter of enzyme mix from *E. coli* followed by the addition of 25 microliter of substrate mix. The resulting mix was incubated for 30 minutes at room temperature with shaking. TNBS solution (50 microliter/well) was added and the resulting mixture was incubated for 15 minutes under shaking. Buffer C was then added (20 microliter/well). After incubating at room temperature for 15 minutes under

72703-dk01

30


shaking, buffer D was added (50 microliter/well). The optical diffraction was then measured at 420 nm, thereby determining the IC₅₀ value.

The assay was repeated using enzyme mix from *S. aureus*.

- 5 The compounds and processes of the invention will be better understood in connection with the following examples, which are intended as an illustration of and not as a limitation upon the scope of the invention.

EXAMPLE 1

- 10 2-(3,4-Dihydro-2H-benzo[1,4]thiazin-2-yl)-N-hydroxy-acetamide



The title compound was prepared according to Method B omitting step 1 in Scheme

B.


- 15 ¹H NMR (MeOD-d₄): δ 7.02-6.94 (m, 2H), 6.19-6.76 (m, 2H), 3.85-3.73 (m, 1H), 3.73 (dd, J = 12.7, 3.25 Hz, 1H), 3.41 (dd, J = 12.2, 6.25 Hz, 1H), 2.55 (dd, J = 7.00, 4.25 Hz, 1H).

IC₅₀ (microM): 56.7 (enzyme from *E. coli*)
37.6 (enzyme from *S. aureus*)

20

EXAMPLE 2

- 2-(1,1-Dioxo-1,2,3,4-tetrahydro-1 λ⁶-benzo[1,4]thiazin-2-yl)-N-hydroxy-acetamide



- 25 The title compound was prepared according to Method B.

Mass found (M+H): 257.022 Mass calculated (M): 256.05


IC₅₀ (microM): 3.4 (enzyme from *E. coli*)
1.5 (enzyme from *S. aureus*).

- 30 **EXAMPLE 3**

2-(4-Ethyl-3,4-dihydro-2H-benzo[1,4]thiazin-2-yl)-N-hydroxy-acetamide

72703-dk01

31



The title compound was prepared according to Method C using acetyl chloride.

Mass found (M+H): 253.153.

Mass calculated (M): 252.09


IC₅₀ (microM): 2.6 (enzyme from *E. coli*)

5.6 (enzyme from *S. aureus*).

5

EXAMPLE 4

2-(4-Ethyl-1,1-dioxo-1,2,3,4-tetrahydro-1λ⁶-benzo[1,4]thiazin-2-yl)-N-hydroxyacetamide



10

The title compound was prepared according to Method A using acetyl chloride.

¹H NMR (MeOD-*d*₄): δ 7.68 (dd, *J* = 8.25, 2.0 Hz, 1H), 7.44 (ddd, *J* = 7.62, 6.75, 1.75 Hz, 1H), 6.91 (d, *J* = 8.75, 1H), 6.81 (t, *J* = 7.00, 1H), 4.10-4.04 (m, 1H), 3.82-3.65 (m, 2H), 3.53 (septet, *J* = 7.5 Hz, 2H), 2.72 (dd, *J* = 15.0, 4.75 Hz, 1H), 2.34 (dd, *J* = 15.0, 9.25 Hz, 1H), 1.21 (t, *J* = 7.0 Hz, 3H).


15

IC₅₀ (microM): 1.4 (enzyme from *E. coli*)

2.0 (enzyme from *S. aureus*).

EXAMPLE 5

N-Hydroxy-2-(4-propyl-3,4-dihydro-2H-benzo[1,4]thiazin-2-yl)-acetamide



The title compound was prepared according to Method C using propionyl chloride.

Mass found (M+H): 267.160.

Mass calculated (M): 266.11


IC₅₀ (microM): 7.0 (enzyme from *E. coli*)

8.5 (enzyme from *S. aureus*).

25

EXAMPLE 6

2-(1,1-Dioxo-4-propyl-1,2,3,4-tetrahydro-1 λ ⁶-benzo[1,4]thiazin-2-yl)-N-hydroxy-acetamide




- 5 The title compound was prepared according to Method A using propionyl chloride.

Mass found (M+H):299.070. Mass calculated (M): 298.10

IC₅₀ (microM): 1.6 (enzyme from *E.coli*)
1.9 (enzyme from *S. aureus*).

10 EXAMPLE 7

2-(4-Butyl-3,4-dihydro-2H-benzo[1,4]thiazin-2-yl)-N-hydroxy-acetamide




The title compound was prepared according to Method C using butyryl chloride.

- 15 Mass found (M+H):281.168. Mass calculated (M): 280.12

IC₅₀ (microM): 22.0 (enzyme from *E.coli*)
35.5 (enzyme from *S. aureus*).

EXAMPLE 8

- 20 2-(4-Butyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ ⁶-benzo[1,4]thiazin-2-yl)-N-hydroxy-acetamide




The title compound was prepared according to Method A using butyryl chloride.

Mass found (M+H):313.082. Mass calculated (M): 312.11

- 25 IC₅₀ (microM): 8.8 (enzyme from *E.coli*)
8.1 (enzyme from *S. aureus*).

EXAMPLE 9

2-(4-Benzyl)-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazin-2-yl)-N-hydroxy-acetamide



5

The title compound was prepared according to Method A benzoyl chloride.


^1H NMR (MeOD- d_4): δ 7.72 (dd, $J = 8.25, 1.5$ Hz, 1H), 7.39-7.22 (m, 6H), 6.87-6.81 (m, 2H), 4.72 (dd, $J = 28.5, 17.5$ Hz, 2H), 4.20 (dd, $J = 13.9, 2.75$ Hz, 1H), 3.86 (dd, $J = 13.25, 7.5$ Hz, 1H), 3.87-3.78 (m, 1H), 2.78 (dd, $J = 15.0, 5.0$ Hz, 1H), 2.38 (dd, $J = 15.0, 8.75$ Hz, 1H).

10

IC_{50} (microM): 21.2 (enzyme from *E. coli*)
21.4 (enzyme from *S. aureus*).

EXAMPLE 10

15 2-[4-(3-Fluoro-benzyl)]-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazin-2-yl)-N-hydroxy-acetamide



The title compound was prepared according to Method A using 3-fluorobenzoyl chloride.

20

Mass found (M+H): 365.040. Mass calculated (M): 364.09


IC_{50} (microM): 27.7 (enzyme from *E. coli*)
28.4 (enzyme from *S. aureus*).

EXAMPLE 11

25 4-Ethyl-2-hydroxycarbonylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid benzylamide

72703-dk01

34



The title compound was prepared according to Method D using benzyl amine.

Mass found (M+H): 418.087.


Mass calculated (M): 417.14

IC₅₀ (microM): 17.6 (enzyme from *E.coli*)

8.9 (enzyme from *S. aureus*).

EXAMPLE 12

4-Ethyl-2-hydroxycarbonylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1λ⁶-benzo[1,4]thiazine-6-carboxylic acid 2-fluoro-benzylamide



The title compound was prepared according to Method D using 2-fluorobenzyl amine.

Mass found (M+H): 436.134.


Mass calculated (M): 435.13

IC₅₀ (microM): 10.8 (enzyme from *E.coli*)

36.8 (enzyme from *S. aureus*).

EXAMPLE 13

4-Ethyl-2-hydroxycarbonylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1λ⁶-benzo[1,4]thiazine-6-carboxylic acid 3-fluoro-benzylamide



The title compound was prepared according to Method D using 3-fluorobenzyl amine.

Mass found (M+H): 436.315.

Mass calculated (M): 435.13

IC₅₀ (microM): 11.7 (enzyme from *E.coli*)


13.7 (enzyme from *S. aureus*).

72703-dk01

35

EXAMPLE 14

4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid 4-fluoro-benzylamide




The title compound was prepared according to Method D using 4-fluorobenzyl amine.

Mass found (M+H): 436.251. Mass calculated (M): 435.13

IC₅₀ (microM): 10.5 (enzyme from *E. coli*)
 10.0 (enzyme from *S. aureus*).

EXAMPLE 15

4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid 2-bromo-benzylamide




The title compound was prepared according to Method D using 2-bromobenzylamine

Mass found (M+H): 496.145. Mass calculated (M): 495.05

IC₅₀ (microM): 20.0 (enzyme from *E. coli*)
 9.6 (enzyme from *S. aureus*).

EXAMPLE 16

4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid 3-bromo-benzylamide



The title compound was prepared according to Method D using 3-bromobenzylamine.

Mass found (M+H): 495.258. Mass calculated (M): 495.05


IC₅₀ (microM): 2.0 (enzyme from *E. coli*)
 9.7 (enzyme from *S. aureus*).

72703-dk01

36

EXAMPLE 17

4-Ethyl-2-hydroxycarbonylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ ⁶-benzo[1,4]thiazine-6-carboxylic acid 4-bromo-benzylamide



5

The title compound was prepared according to Method D using 4-bromobenzylamine.


Mass found (M+H): 496.081. Mass calculated (M): 495.05

IC₅₀ (microM): 1.5 (enzyme from *E. coli*)
 3.4 (enzyme from *S. aureus*).

10

EXAMPLE 18

4-Ethyl-2-hydroxycarbonylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ ⁶-benzo[1,4]thiazine-6-carboxylic acid 2-nitro-benzylamide



15

The title compound was prepared according to Method D using 2-nitrobenzylamine.


Mass found (M+H): 463.222. Mass calculated (M): 462.12

IC₅₀ (microM): 17.6 (enzyme from *E. coli*)
 11.3 (enzyme from *S. aureus*).

20

EXAMPLE 19

4-Ethyl-2-hydroxycarbonylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ ⁶-benzo[1,4]thiazine-6-carboxylic acid 3-nitro-benzylamide



25

The title compound was prepared according to Method D using 3-nitrobenzylamine.

Mass found (M+H): 463.286. Mass calculated (M): 462.12


IC₅₀ (microM): 3.3 (enzyme from *E. coli*)
 11.9 (enzyme from *S. aureus*).

72703-dk01

37

EXAMPLE 20

4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid 4-nitro-benzylamide



5

The title compound was prepared according to Method D using 4-nitrobenzylamine.


Mass found (M+H): 463.222. Mass calculated (M): 462.12

IC₅₀ (microM): 1.2 (enzyme from *E. coli*)
 3.9 (enzyme from *S. aureus*).

10

EXAMPLE 21

4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid 2-methoxy-benzylamide




15 The title compound was prepared according to Method D using 2-methoxybenzylamine.

Mass found (M+H): 448.281. Mass calculated (M): 447.15

IC₅₀ (microM): 1.5 (enzyme from *E. coli*)
 1.5 (enzyme from *S. aureus*).

20 EXAMPLE 22

4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid 3-methoxy-benzylamide




25 The title compound was prepared according to Method D using 3-methoxybenzylamine

Mass found (M+H): 448.102. Mass calculated (M): 447.15

IC₅₀ (microM): 1.0 (enzyme from *E. coli*)
 2.3 (enzyme from *S. aureus*).

EXAMPLE 23

4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ ⁶-benzo[1,4]thiazine-6-carboxylic acid 4-methoxy-benzylamide




- 5 The title compound was prepared according to Method D using 4-methoxybenzylamine.

Mass found (M+H): 448.281. Mass calculated (M): 447.15

IC₅₀ (microM): 4.9 (enzyme from *E. coli*)
13.1 (enzyme from *S. aureus*).

10 EXAMPLE 24

4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ ⁶-benzo[1,4]thiazine-6-carboxylic acid 3-trifluoromethyl-benzylamide



The title compound was prepared according to Method D using 3-


- 15 trifluoromethylbenzylamine.

Mass found (M+H): 486.268. Mass calculated (M): 485.12

IC₅₀ (microM): 2.0 (enzyme from *E. coli*)
8.3 (enzyme from *S. aureus*).

20 EXAMPLE 25

4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ ⁶-benzo[1,4]thiazine-6-carboxylic acid 4-trifluoromethyl-benzylamide



The title compound was prepared according to Method D using 4-

- 25 trifluoromethylbenzylamine.

Mass found (M+H): 486.205. Mass calculated (M): 485.12


IC₅₀ (microM): <200 (enzyme from *E. coli*)
4.2 (enzyme from *S. aureus*).

72703-dk01

39

EXAMPLE 26

4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid 4-trifluoromethoxybenzylamide



- 5 The title compound was prepared according to Method D using 4-trifluoromethoxybenzylamine.


Mass found (M+H): 502.286. Mass calculated (M): 501.12

IC₅₀ (microM): 1.1 (enzyme from *E. coli*)
5.0 (enzyme from *S. aureus*).

10

EXAMPLE 27

4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid 4-dimethylaminobenzylamide



- 15 The title compound was prepared according to Method D using 4-dimethylaminobenzylamine.


Mass found (M+H): 461.147. Mass calculated (M): 460.18

IC₅₀ (microM): 9.3 (enzyme from *E. coli*)
18.2 (enzyme from *S. aureus*).

20

EXAMPLE 28

4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid (pyridin-4-ylmethyl)-amide



- 25 The title compound was prepared according to Method D using 4-pyridylmethylamine.

Mass found (M+H): 419.100. Mass calculated (M): 418.13


IC₅₀ (microM): > 200 (enzyme from *E. coli*)
70.5 (enzyme from *S. aureus*).

72703-dk01

40

EXAMPLE 29

4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid (thiophen-2-ylmethyl)-amide




- 5 The title compound was prepared according to Method D using 2-thienylmethylamine.

Mass found (M+H): 424.039. Mass calculated (M): 423.09

IC₅₀ (microM): 9.5 (enzyme from *E.coli*)
3.4 (enzyme from *S. aureus*).

10 EXAMPLE 30

4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid (1H-pyrazol-3-yl)-amide




The title compound was prepared according to Method D using 1H-pyrazol-3-ylamine.

- 15 Mass found (M+H): 394.152. Mass calculated (M): 393.11

IC₅₀ (microM): 11.5 (enzyme from *E.coli*)
30.8 (enzyme from *S. aureus*).

EXAMPLE 31

- 20 4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid thiazol-2-ylamide



The title compound was prepared according to Method D using thiazol-2-ylamine.

Mass found (M+H): 411.058. Mass calculated (M): 410.07


- 25 IC₅₀ (microM): 12.3 (enzyme from *E.coli*)
20.8 (enzyme from *S. aureus*).

72703-Jk01

41

EXAMPLE 32

2-[4-Ethyl-6-(4-methyl-piperazine-1-carbonyl)-1,1-dioxo-1,2,3,4-tetrahydro-1 λ ⁶-benzo[1,4]thiazin-2-yl]-N-hydroxy-acetamide




- 5 The title compound was prepared according to Method D using N-methylpiperazine.

Mass found (M+H): 411.185. Mass calculated (M): 410.16

IC₅₀ (microM): > 200 (enzyme from *E. coli*)
128.0 (enzyme from *S. aureus*).

10 EXAMPLE 33

4-Ethyl-2-hydroxycarbonylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ ⁶-benzo[1,4]thiazine-6-carboxylic acid (5-thiophen-2-yl-2H-pyrazol-3-yl)-amide



The title compound was prepared according to Method D using 5-thiophen-2-yl-2H-pyrazol-


- 15 3-ylamine.

Mass found (M+H): 476.028. Mass calculated (M): 475.10

IC₅₀ (microM): 0.9 (enzyme from *E. coli*)
3.0 (enzyme from *S. aureus*).

20 EXAMPLE 34

4-Ethyl-2-hydroxycarbonylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ ⁶-benzo[1,4]thiazine-6-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide



The title compound was prepared according to Method D using 8-methyl-8-aza-

- 25 bicyclo[3.2.1]oct-3-ylamine.

Mass found (M+H): 451.141. Mass calculated (M): 450.19


72703-dk01

42

IC₅₀ (microM): 13.8 (enzyme from *E. coli*)
6.0 (enzyme from *S. aureus*).

EXAMPLE 35

- 5 2-(4-Cyclopropylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1λ⁶-benzo[1,4]thiazin-2-yl)-N-hydroxy-acetamide




The title compound was prepared according to Method A using cyclopropylcarbonyl chloride.

- 10 ¹H NMR (MeOD-*d*₄): δ 7.70 (dd, *J* = 7.87, 1.25 Hz, 1H), 7.46 (ddd, *J* = 8.75, 7.0, 2.0 Hz, 1H), 7.02 (d, *J* = 8.25, 1H), 6.84 (t, *J* = 7.00, 1H), 4.18 (dd, *J* = 13.2, 2.75 Hz, 1H), 3.89 (dd, *J* = 13.7, 6.75 Hz, 1H), 3.75-3.66 (m, 1H), 3.49 (dd, *J* = 15.0, 6.5 Hz, 1H), 3.27 (dd, *J* = 15.0, 7.5 Hz, 1H), 2.73 (dd, *J* = 15.0, 4.75 Hz, 1H), 2.36 (dd, *J* = 16.2, 9.25 Hz, 1H), 1.19-1.05 (m, 1H), 0.65-0.57 (m, 2H), 0.38-0.35 (m, 2H).

- 15 IC₅₀ (microM): 2.1 (enzyme from *E. coli*)
4.8 (enzyme from *S. aureus*).

EXAMPLE 36

- 20 2-(4-Cyclobutylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1λ⁶-benzo[1,4]thiazin-2-yl)-N-hydroxy-acetamide



The title compound was prepared according to Method A using cyclobutylcarbonyl chloride.

Mass found (M+H): 325.111. Mass calculated (M): 324.11


- 25 IC₅₀ (microM): 3.3 (enzyme from *E. coli*)
3.8 (enzyme from *S. aureus*).

EXAMPLE 37

- 2-(4-Cyclopentylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1λ⁶-benzo[1,4]thiazin-2-yl)-N-hydroxy-acetamide

72703-dk01

43



The title compound was prepared according to Method A using cyclopentylcarbonyl chloride.


Mass found (M+H): 339.060. Mass calculated (M): 338.13

IC₅₀ (microM): 11.1 (enzyme from *E. coli*)
13.9 (enzyme from *S. aureus*).

5

EXAMPLE 38

2-(4-Cyclohexylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1λ⁶-benzo[1,4]thiazin-2-yl)-N-hydroxy-
acetamide



10

The title compound was prepared according to Method A using cyclohexylcarbonyl chloride.

Mass found (M+H): 353.074. Mass calculated (M): 352.15

IC₅₀ (microM): 33.2 (enzyme from *E. coli*)
18.1 (enzyme from *S. aureus*).

15

The invention described and claimed herein is not to be limited in scope by the specific embodiments herein disclosed, since these embodiments are intended as illustrations of several aspects of the invention. Any equivalent embodiments are intended to be within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims.

20

Various references are cited herein, the disclosure of which are incorporated by reference in their entireties.

72703-dk01

44

LITERATURE LIST

Adams, J. M.; Capecchi, M. R. *Proc. Natl. Acad. Sci., USA*, 1966, 55, 147-155.

5 Adams, J. M. *J. Mol. Biol.* 1968, 33, 571-589.

Clements, J. M.; Ayscough, A. P.; Keavey, K.; East, S. P. *Curr. Med. Chem. Anti-Infective Agents* 2002, 1, 239-249.

10 Gennaro, A. R.; Gennaro A. L. *Remington, The Science and Practice of Pharmacy*, 19th ed., Mack Publishing Co., Easton, Pa., 1995.

Giglione, C.; Pierre, M.; Meimmel, T. *Mol. Microbiol.* 2000, 36, 1197-1205.

15 Giglione, C.; Mcinncl, T. *Emerg. Ther. Targets* 2001, 5, 41-57.

Green, T. W. *Protective Groups In Organic Synthesis*, John Wiley & Sons, New York, 1981.

Pci, D. *Emerg. Ther. Targets* 2001, 5, 23-40.

20

Yuan, Z.; Trias, J.; White, R. J. *Drug Discov. Today* 2001, 6, 954-961.


72703-uk01

52

ABSTRACT

PEPTIDE DEFORMYLASE INHIBITORS

Benzothiazine compounds of the general formula (I)



(I)

and pharmaceutically acceptable salts or esters thereof are peptide deformylase inhibitors useful in the treatment or prevention of infections and other diseases in which peptide deformylases are involved, especially in the treatment of bacterial and parasitic infections, for example infections fully or partly caused by microorganisms belonging to *Staphylococcus*, *Enterococcus*, *Streptococcus*, *Haemophilus*, *Moraxella*, *Escherichia*, *Mycobacterium*, *Mycoplasma*, *Pseudomonas*, *Chlamydia*, *Rickettsia*, *Klebsiella*, *Shigella*, *Salmonella*, *Bordetella*, *Clostridium*, *Helicobacter*, *Campylobacter*, *Legionella* or *Neisseria*.

BEST AVAILABLE COPY

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.


**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

72703-dk01

45

CLAIMS

1. A compound of formula (I)



(I)

or a pharmaceutically acceptable salt or ester thereof,

wherein

X is -CONHOH, -COOH or -N(OH)COH;

n is zero or an integer 1 or 2;

10 m is an integer 1, 2, 3 or 4;

R₁ is selected from the group consisting of hydrogen, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₃₋₁₀ cycloalkyl, C₁₋₆ alkyl-C₃₋₁₀ cycloalkyl, C₃₋₇ heterocycloalkyl, C₁₋₆ alkoxy, C₁₋₆ alkylamino, C₁₋₆ alkylmercapto, C₁₋₆ alkylhydroxy, C₁₋₆ alkylthio, alkylamino-C₁₋₆alkyl, dialkylamino-C₁₋₆alkyl; and any aryl, heteroaryl, C₁₋₆ alkylaryl or C₁₋₆ alkylheteroaryl optionally substituted with one or more substituents independently selected from halogen, hydroxy, amino, mercapto, nitro, cyano, trifluoromethyl, C₁₋₆ alkyl, C₁₋₆ alkoxy and C₁₋₆ alkylthio;

one of R₂ and R₃ is selected from the group consisting of halogen, hydrogen, carboxylic acid, -CONR₄R₅ and -CONHR₅, in which R₄ and R₅ are identical or different and independently of each other are selected from the group consisting of C₃₋₇ heterocycloalkyl and any of C₁₋₆ alkyl-C₃₋₇ heterocycloalkyl, aryl, heteroaryl, C₁₋₆ alkylaryl and C₁₋₆ alkylheteroaryl optionally substituted with one or more substituents independently selected from halogen, hydroxy, amino, mercapto, nitro, cyano, trifluoromethyl, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkylthio, C₁₋₆ alkylhydroxy, C₁₋₆ alkylamino, alkylamino-C₁₋₆alkyl and dialkylamino-C₁₋₆alkyl; and

the other of R₂ and R₃ is selected from the group consisting of hydrogen, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₃₋₁₀ cycloalkyl, C₁₋₆ alkyl-C₃₋₁₀ cycloalkyl, C₃₋₇ heterocycloalkyl, C₁₋₆ alkoxy, C₁₋₆ alkylamino, C₁₋₆ alkylmercapto, C₁₋₆ alkylhydroxy, C₁₋₆ alkylthio, alkylamino-C₁₋₆alkyl, dialkylamino-C₁₋₆alkyl; and any aryl, heteroaryl, C₁₋₆ alkylaryl or C₁₋₆ alkylheteroaryl optionally substituted with one or more substituents independently selected from halogen, hydroxy, amino, mercapto, nitro, cyano, trifluoromethyl, C₁₋₆ alkyl, C₁₋₆ alkoxy and C₁₋₆ alkylthio.

72703-dk01

46

2. The compound according to claim 1, wherein X is -CONHOH.
3. The compound according to claim 1, wherein X is -COOH.
- 5 4. The compound according to claim 1, wherein X is -N(OH)COH.
5. The compound according to claim 1, wherein R₁ is selected from the group consisting of
hydrogen, C₁₋₆ alkyl, C₃₋₁₀ cycloalkyl, C₁₋₆ alkyl-C₃₋₁₀ cycloalkyl, C₁₋₆ alkylamino, C₁₋₆
10 alkylhydroxy; and any aryl, C₁₋₆ alkylaryl or C₁₋₆ alkylheteroaryl optionally substituted with
one or more substituents independently selected from halogen, hydroxy, amino, mercapto,
nitro, cyano, trifluoromethyl, C₁₋₆ alkyl, C₁₋₆ alkoxy, and C₁₋₆ alkylthio.
6. The compound according to claim 1, wherein R₁ is selected from the group consisting of
15 hydrogen, methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, methyl
cyclopropyl, methyl cyclobutyl, methyl cyclohexyl, ethyl cyclohexyl, ethylamino,
propylamino, butylamino, methylhydroxy, ethylhydroxy, propylhydroxy, butylhydroxy,
phenyl, benzyl, fluorosubstituted phenyl, fluorosubstituted benzyl, chlorosubstituted phenyl,
chlorosubstituted benzyl, bromo substituted phenyl and bromo substituted benzyl.
- 20 7. The compound according to claim 1, wherein one of R₂ and R₃ is hydrogen, fluorine,
chlorine, bromine, iodine or carboxylic acid.
8. The compound according to claim 1, wherein one of R₂ and R₃ is -CONHR₅ or
25 -CONR₄R₅.
9. The compound according to claim 1, wherein one of R₂ and R₃ is hydrogen or C₃₋₇
heterocycloalkyl; or aryl, heteroaryl, C₁₋₆ alkylaryl or C₁₋₆ alkylheteroaryl optionally
substituted with one or more substituents independently selected from halogen, hydroxy,
30 amino, mercapto, nitro, cyano, trifluoromethyl, C₁₋₆ alkyl, C₁₋₆ alkoxy and C₁₋₆ alkylthio.
10. The compound according to claim 1, wherein R₄ or R₅ is C₃₋₇ heterocycloalkyl, C₁₋₆ alkyl-
C₃₋₇ heterocycloalkyl, heteroaryl or C₁₋₆ alkylheteroaryl having one or more heteroatoms
selected among N, O and S.

72703-dk01

47

11. The compound according to claim 1, wherein R_4 or R_5 is aryl, heteroaryl, C_{1-6} alkylaryl or C_{1-6} alkylheteroaryl, any of which may be substituted with one or more substituents independently selected from halogen, hydroxy, amino, mercapto, nitro, cyano,
- 5 trifluoromethyl, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkylthio, C_{1-6} alkylhydroxy, C_{1-6} alkylamino, alkylamino- C_{1-6} alkyl and dialkylamino- C_{1-6} alkyl.
12. The compound according to claim 1, wherein R_4 or R_5 is selected from a group consisting of benzyl; mono-, di-, tri- or tetra-fluoro-substituted benzyl, mono-, di-, tri- or tetra-bromo-
- 10 substituted benzyl, trifluoromethyl substituted benzyl, trifluoromethoxy substituted benzyl, dimethylamino substituted benzyl, nitro substituted benzyl, 5-thiophen-2-yl-2H-pyrazol-3-yl, 8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl, methylpyridyl, methyl-2-thienyl, 3-pyrazolyl, 2-thiazolyl, 4-methyl-1-piperazinyl.
13. The compound according to claim 1, wherein R_3 is selected from a group consisting of hydrogen and 1-piperazinyl.
14. The compound according to claim 1 selected from the group consisting of
- 20 2-(3,4-Dihydro-2H-benzo[1,4]thiazin-2-yl)-N-hydroxy-acetamide
2-(1,1-Dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazin-2-yl)-N-hydroxy-acetamide
2-(4-Ethyl-3,4-dihydro-2H-benzo[1,4]thiazin-2-yl)-N-hydroxy-acetamide
2-(4-Ethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazin-2-yl)-N-hydroxy-acetamide
N-Hydroxy-2-(4-propyl-3,4-dihydro-2H-benzo[1,4]thiazin-2-yl)-acetamide
2-(1,1-Dioxo-4-propyl-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazin-2-yl)-N-hydroxy-acetamide
- 25 2-(4-Butyl-3,4-dihydro-2H-benzo[1,4]thiazin-2-yl)-N-hydroxy-acetamide
2-(4-Butyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazin-2-yl)-N-hydroxy-acetamide
2-(4-Benzyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazin-2-yl)-N-hydroxy-acetamide
2-[4-(3-Fluoro-benzyl)-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazin-2-yl]-N-hydroxy-acetamide
- 30 4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid benzylamide
4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid 2-fluoro-benzylamide

72703-dk01

48

- 4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid 3-fluoro-benzylamide
- 4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid 4-fluoro-benzylamide
- 5 4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid 2-bromo-benzylamide
- 4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid 3-bromo-benzylamide
- 4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid 4-bromo-benzylamide
- 10 4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid 2-nitro-benzylamide
- 4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid 3-nitro-benzylamide
- 15 4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid 4-nitro-benzylamide
- 4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid 2-methoxy-benzylamide
- 4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid 3-methoxy-benzylamide
- 20 4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid 4-methoxy-benzylamide
- 4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid 3-trifluoromethyl-benzylamide
- 25 4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid 4-trifluoromethyl-benzylamide
- 4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid 4-trifluoromethoxybenzylamide
- 4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid 4-dimethylaminobenzylamide
- 30 4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid (pyridin-4-ylmethyl)-amide

72703-dk01

49

- 4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid (thiophen-2-ylmethyl)-amide
4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid (1H-pyrazol-3-yl)-amide
- 5 4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid thiazol-2-ylamide
2-[4-Ethyl-6-(4-methyl-piperazine-1-carbonyl)-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazin-2-yl]-N-hydroxy-acetamide
4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-
- 10 carboxylic acid (5-thiophen-2-yl-2H-pyrazol-3-yl)-amide
4-Ethyl-2-hydroxycarbamoylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazine-6-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide
2-(4-Cyclopropylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazin-2-yl)-N-hydroxy-acetamide
- 15 2-(4-Cyclobutylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazin-2-yl)-N-hydroxy-acetamide
2-(4-Cyclopentylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazin-2-yl)-N-hydroxy-acetamide, and
2-(4-Cyclohexylmethyl-1,1-dioxo-1,2,3,4-tetrahydro-1 λ^6 -benzo[1,4]thiazin-2-yl)-N-hydroxy-
- 20 acetamide.

15. The compound according to claim 1, which exhibits an IC₅₀ value of less than 500 μ M, preferably less than 100 μ M, more preferably less than 50 μ M, even more preferably less than 1 μ M, especially less than 500 nM, particularly less than 100 nM.
- 25 16. A pharmaceutical composition comprising, as an active ingredient, a compound according to any of the preceding claims or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.
- 30 17. The composition according to claim 16 comprising a second active ingredient having antibacterial activity.

72703-dk01

50

18. The composition according to claim 16 in unit dosage form, comprising from about 0.05 to about 500 mg, preferably from about 0.1 to about 100 mg, more preferably from about 0.1 to about 50 mg of the compound according to claim 1 or a pharmaceutically acceptable salt or ester thereof.

5

19. A pharmaceutical composition for treatment of infections, the composition comprising, as an active ingredient, a compound according to claim 1 or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.

10

20. The pharmaceutical composition according to claim 19 for the treatment of bacterial infections fully or partly caused by an organism belonging to any of the genera *Staphylococcus*, *Enterococcus*, *Streptococcus*, *Haemophilus*, *Moraxella*, *Escherichia*, *Mycobacteria*, *Mycoplasma*, *Pseudomonas*, *Chlamydia*, *Rickettsia*, *Klebsiella*, *Shigella*, *Salmonella*, *Bordetella*, *Clostridia*, *Helicobacter*, *Campylobacter*, *Legionella* and *Neisseria*.

15

21. The pharmaceutical composition according to any of the claims 16, 17, 18, 19 and 20 for oral, nasal, transdermal, pulmonal or parenteral administration.

22. A method for the treatment of ailments, the method comprising administering to a subject in need thereof an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof, or of a composition according to any of the claims 16, 17, 18, 19, 20 and 21.

23. The method according to claim 22, wherein the effective amount of the compound according to claim 1 or a pharmaceutically acceptable salt or ester thereof is in the range of from about 0.05 to about 100 mg per day, preferably from about 0.1 to about 50 mg per day.

25

24. Use of a compound according to claim 1 or a pharmaceutically acceptable salt thereof for the preparation of a medicament.

30

25. Use of a compound according to claim 1 or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treatment of bacterial infections.

72703-JK01

51

26. Use of a compound according to claim 1 or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treatment of an infection fully or partly caused by an organism belonging to the group consisting of *Staphylococcus*, *Enterococcus*, *Streptococcus*, *Haemophilus*, *Moraxella*, *Escherichia*, *Mycobacteria*, *Mycoplasma*, *Pseudomonas*,
5 *Chlamydia*, *Rickettsia*, *Klebsiella*, *Shigella*, *Salmonella*, *Bordetella*, *Clostridia*, *Helicobacter*, *Campylobacter*, *Legionella* and *Neisseria*.
27. Use of a compound according to claim 1 or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treatment of an infection fully or partly caused by an
10 organism belonging to the group consisting of *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Enterococcus faecium*, *Enterococcus faecalis*, *Streptococcus pneumoniae*, *Haemophilus influenzae*, *Moraxella catarrhalis*, *Escherichia coli*, *Mycobacterium tuberculosis*, *Mycobacterium ranarum*, *Mycoplasma pneumoniae*, *Pseudomonas aeruginosa*, *Chlamydia*, *Rickettsiae*, *Klebsiella pneumoniae*, *Shigella flexneri*, *Salmonella typhimurium*,
15 *Bordetella pertussis*, *Clostridia perfringens*, *Helicobacter pylori*, *Campylobacter jejuni*, *Legionella pneumophila* and *Neisseria gonorrhoeae*.